Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Perinez, also known by its brand name ADVATE or the Chinese name 百因止, is a recombinant human coagulation Factor VIII used for the treatment and prevention of bleeding in patients with Hemophilia A. Hemophilia A is a genetic bleeding disorder caused by a deficiency of Factor VIII, an essential blood clotting protein. Perinez works by replacing the missing Factor VIII, which acts as a cofactor for Factor IXa in the coagulation cascade, leading to the activation of Factor X and subsequent clot formation. It is a third-generation recombinant factor product, produced using gene recombination technology in Chinese hamster ovary cells, and is free from blood components, thereby reducing the risk of transmitting blood-borne pathogens.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Perinez.